Fig. 5
From: Arbaclofen in fragile X syndrome: results of phase 3 trials
Dose responses for change in the CGI-I (a) and percent responders in responder analysis (b) in child study. Responders are defined as subjects with 25% improvement in the primary outcome ABC-CFX Social Avoidance plus a CGI-I of 1 or 2